Genmab — April 2021
-
Umiddelbart virker det til, at kontrakten er lavet over en slags standardformular for royalty agreements. Mange af kontraktens specifics er overstregede - og offentligheden har derfor ikke adgang til den egentlige ordlyd. Enhver vurdering af sagen lader til at være mere holdning end egentlig substans
-
Nogen må have moret sig bekosteligt den første time her til morgen
-
that is fast for a change...: NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta https://pharmaphorum.com/news/nice-says-yes-to-novartis-multiple-sclerosis-therapy-kesimpta/
-
NICE says yes - truly revolutionary. Are they giving Kesimpta away for free?
-
Hvem tør skyde på Q1 dara tal fra J&J?
-
Er det kl. 12?
-
Ca. 12:40
-
Tak Plimsoller.
-
Velbekomme. Informationen kom fra GB i går 07:57, så "kreditten" går til, ham.
-
Johnson & Johnson Reports 2021 First-Quarter Results:
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. "Johnson & Johnson delivered a strong first quarter performance...
(www.prnewswire.com)
-
Very impressive:-)
-
Genmab guidance alt alt for lav
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind